NASDAQ:NKNantkwest Stock Price, Forecast & News

Nantkwest's stock was trading at $3.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NK shares have increased by 292.0% and is now trading at $13.80. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nantkwest.

Nantkwest is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Nantkwest.

Nantkwest Inc (NASDAQ:NK) posted its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. Nantkwest had a negative return on equity of 51.94% and a negative net margin of 112,350.85%. View Nantkwest's earnings history.

1 equities research analysts have issued twelve-month price targets for Nantkwest's stock. Their forecasts range from $18.00 to $18.00. On average, they anticipate Nantkwest's share price to reach $18.00 in the next year. This suggests a possible upside of 30.4% from the stock's current price. View analysts' price targets for Nantkwest.

News coverage about NK stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nantkwest earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Nantkwest.

Nantkwest saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 4,670,000 shares, an increase of 8.4% from the June 15th total of 4,310,000 shares. Based on an average trading volume of 2,020,000 shares, the days-to-cover ratio is currently 2.3 days. Approximately 16.7% of the company's shares are sold short. View Nantkwest's Current Options Chain.

Some companies that are related to Nantkwest include Acceleron Pharma (XLRN), Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), bluebird bio (BLUE), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Immunovant (IMVT), Alector (ALEC) and Editas Medicine (EDIT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nantkwest investors own include Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Novavax (NVAX), Mallinckrodt (MNK), Opko Health (OPK), Amicus Therapeutics (FOLD), NovaBay Pharmaceuticals (NBY), Bausch Health Companies (BHC), Fate Therapeutics (FATE) and Immunomedics (IMMU).

(NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Nantkwest's stock is owned by many different institutional and retail investors. Top institutional investors include TRUE Private Wealth Advisors (0.00%). Company insiders that own Nantkwest stock include Barry J Simon, John C Thomas, Patrick Soon-Shiong and Steve Gorlin. View institutional ownership trends for Nantkwest.

NK stock was purchased by a variety of institutional investors in the last quarter, including TRUE Private Wealth Advisors. View insider buying and selling activity for Nantkwest.

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NK stock can currently be purchased for approximately $13.80.

Nantkwest has a market capitalization of $1.36 billion and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Nantkwest employs 161 workers across the globe.

The official website for Nantkwest is www.nantkwest.com.

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]